Barraud S, Guédra L, Delemer B, et al. - Researchers conducted this two-centre, retrospective, observational study to assess the evolution of macroprolactinomas, defined as an adenoma ≥ 10 mm at diagnosis on MRI and a prolactin plasma level > 150 µg/L, during pregnancy and to discover potential risk factors. It included all patients with macroprolactinomas, treated with a dopamine receptor agonist (DA), who had at least one pregnancy. In 46 patients with macroprolactinomas, there were a total of 85 viable pregnancies. In 19.6% of medically treated patients, symptomatic growth of macroprolactinoma during pregnancy occurred. The risk for patients with poor initial tumor response to treatment with DA tends to be higher. In general, tumor progression is well controlled during pregnancy with medical treatment.